Novartis agreed to pay $125 million to secure global rights to Sironax’s blood-brain barrier crossing platform, extending the startup’s reach while transferring core technology. The transaction is tied to Sironax’s option, originally disclosed in July 2025. Sironax will receive $125 million at closing and retain development, manufacturing, and commercialization rights for selected assets using the acquired platform. Novartis gains a technology intended to move a range of modalities into the central nervous system, and the proceeds are expected to support three clinical-stage programs and additional early candidates at Sironax.